Inflammatory Bowel Disease Treatment Market Forecast Signals New Revenue Opportunities Through 2030
Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.
Inflammatory Bowel Disease Treatment Market Revenue Outlook: What CAGR Is Expected Through 2030?
The market for treating inflammatory bowel disease has experienced robust expansion in recent years. Its valuation is projected to rise from $27.19 billion in 2025 to $29.8 billion in 2026, representing a compound annual growth rate (CAGR) of 9.6%. Several factors contributed to this growth during the historic period, including a higher incidence of ulcerative colitis and Crohn’s disease, increased knowledge about available IBD therapies, the broadening of hospital and retail pharmacy networks, the accessibility of generic aminosalicylates, and the early integration of biologic treatments in developed areas.
The inflammatory bowel disease treatment market is anticipated to experience robust expansion over the coming years. By 2030, it is projected to reach a valuation of $43.36 billion, reflecting a compound annual growth rate (CAGR) of 9.8%. This forecasted growth is driven by heightened investment in precision medicine, the emergence of novel anti-inflammatory therapies, the incorporation of digital health platforms for monitoring patients, increased uptake of biologics and biosimilars, and broader access to IBD care in developing markets. Key trends shaping this period include the advancement of personalized IBD treatments, a rising reliance on biologic therapies, the adoption of minimally invasive drug delivery methods, a greater emphasis on patient adherence initiatives, and the expansion of specialty pharmacies focused on IBD management.
Download A Free Sample Report For Comprehensive Market Insights:
Inflammatory Bowel Disease Treatment Market Demand Drivers Creating New Revenue Opportunities
The increasing occurrence of Crohn’s disease and ulcerative colitis is a major factor propelling the inflammatory bowel disease treatment market forward. These two conditions, classified as forms of inflammatory bowel disease (IBD), trigger digestive tract inflammation and the formation of ulcers. As the number of individuals diagnosed with Crohn’s disease and ulcerative colitis rises, the need for effective treatments is anticipated to grow, given that these therapies are extensively employed to alleviate bowel inflammation and prevent further complications. A case in point is data from November 2024, released by the Crohn’s & Colitis Foundation, a US non-profit, which indicates that about 100,429 children and adolescents under the age of 20 in the United States are living with IBD, which includes both Crohn’s disease and ulcerative colitis. Within this pediatric group, Crohn’s disease shows a higher prevalence rate of 71 per 100,000, while ulcerative colitis stands at 44 per 100,000. Consequently, the growing prevalence of these conditions is set to fuel expansion of the inflammatory bowel disease treatment market.
Inflammatory Bowel Disease Treatment Market Segmentation: How Is The Market Structured Across Key Categories?
The inflammatory bowel disease treatment market covered in this report is segmented –
1) By Drug Class: Aminosalicylates, Corticosteroids, TNF inhibitors, IL inhibitors, Anti-integrin, JAK inhibitors, Other Drug Classes
2) By Type: Crohn’s Disease, Ulcerative Colitis
3) By Route Of Administration: Oral, Injectable
4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
Subsegments:
1) By Aminosalicylates: Mesalamine, Sulfasalazine, Balsalazide
2) By Corticosteroids: Prednisone, Budesonide, Hydrocortisone
3) By TNF Inhibitors: Infliximab, Adalimumab, Certolizumab pegol
4) By IL Inhibitors: Ustekinumab, Guselkumab
5) By Anti-Integrin: Vedolizumab, Natalizumab
6) By JAK Inhibitors: Tofacitinib, Filgotinib
7) By Other Drug Classes: Antibiotics, Immunosuppressants, Other Novel Therapies
Inflammatory Bowel Disease Treatment Market Trends Driving Strategic Industry Expansion
Key industry players in the market for inflammatory bowel disease therapies are introducing cutting-edge products, such as treatments for moderate to severe active ulcerative colitis, aimed at reaching broader audiences, boosting sales, and driving higher profits. Therapeutic approaches for moderate to severe active ulcerative colitis often incorporate pharmacological solutions and, in some cases, surgical procedures. As an example, in October 2023, Eli Lilly and Company, a pharmaceutical firm based in the United States, received clearance from the U.S. Food and Drug Administration (FDA) for Omvoh (mirikizumab-mrkz), presented in both an infusion form (300 mg/15 mL) and an injectable version (100 mg/mL). This medication is the first and only interleukin-23p19 (IL-23p19) antagonist created to manage adults diagnosed with moderately to severely active ulcerative colitis (UC). Omvoh is precisely engineered to target the p19 subunit of IL-23, thereby inhibiting the IL-23 pathway, a key driver of inflammation that plays a major role in the onset of UC. The dosing schedule for Omvoh starts with three 300-mg intravenous infusions given once every four weeks, followed by a maintenance stage that consists of two 100-mg subcutaneous self-administered injections every four weeks.
Inflammatory Bowel Disease Treatment Market Competitive Landscape And Leading Companies
Major companies operating in the inflammatory bowel disease treatment market are AbbVie Inc., Biogen Inc., Johnson & Johnson, Amgen Inc., Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Celgene Corporation, Eli Lilly and Company, Gilead Sciences Inc., GlaxoSmithKline plc, Merck & Co. Inc., Novartis International AG, Pfizer Inc., F. Hoffmann-La Roche Ltd, Takeda Pharmaceutical Company Limited, Salix Pharmaceuticals Inc., Vifor Pharma AG, Zydus Pharmaceuticals (USA) Inc., Advanced Gastroenterology and Surgery Associates P.A., Atlanta Gastroenterology Associates LLC, Digestive Disease Associates of Rockland P.C., Gastrointestinal Specialists Inc., Illinois Gastroenterology Group LLC, Massachusetts General Hospital, Mayo Clinic, Mount Sinai Health System Inc., The Oregon Clinic – Gastroenterology West P.C.
Access The Complete Inflammatory Bowel Disease Treatment Market Report:
Inflammatory Bowel Disease Treatment Market Leading Geography: Which Region Generates The Most Revenue?
North America was the largest region in the inflammatory bowel disease treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the inflammatory bowel disease treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
